WATERTOWN, Mass., May 25, 2017 -- Two new studies from Postgraduate Medical Journal indicate that when used throughout a hospital, Exergen TemporalScanners deliver substantial cost savings while providing accuracy and ease of use, as supported by more than 70 peer-reviewed published studies for all ages and clinical settings.
The first study, “Cost minimisation analysis of thermometry in two different hospital systems1,” was conducted at University Hospital Centre Zagreb (UHCZ) and University of Michigan Hospitals (UMH), each of which used the Exergen TAT-5000 to evaluate cost savings. Results dramatically favored TAT over tympanic thermometry at UHCZ, where the cost of consumables per measurement would be more than 10 times cheaper for TAT, leading to considerable budget savings within a year of hospital-wide implementation. The UMH study concluded that routine use of Exergen TAT-5000 would lead to cost savings over three years at UMH.
The second study, “Minimising the costs of temperature monitoring in hospitals2,” revealed that Exergen TAT-5000 savings exceeded $1.7 million when there were 10 beds per device used for five years. In addition, the study indicated that other forms of thermometry such as oral, axillary and rectal are not favored by hospital staff due to numerous factors including time commitment needed from the healthcare provider, patient discomfort and the potential to wake a sleeping patient.
“We appreciate how cost is a critical consideration in hospital purchasing today, and we are committed to providing a product, the Exergen TAT-5000, that delivers significant cost savings,” said Francesco Pompei, Ph.D., CEO of Exergen Corporation. “This has wide implications for maximizing savings, as our thermometer is the single standard of uniform care in hospitals nationwide, giving more healthcare professionals and patients access to its many benefits.”
The above, along with other independent studies, confirm suitability among all patient groups, including premature infants, adults and geriatrics, and under all medical conditions. For a complete list of studies visit www.exergen.com/c.
ABOUT EXERGEN CORPORATION
Exergen manufactures and markets two types of the TemporalScanner thermometer: a professional version for doctors' offices and hospitals, and a consumer model sold in major retailers nationwide. Nearly two billion temperatures are taken each year with the TemporalScanner. It is used in thousands of hospitals, clinics and pediatricians' offices across the country, as well as in millions of homes. It is the #1 preference of pediatricians, #1 preference of nurses in the US, and #1 selling retail thermometer. The Exergen TemporalScanner's performance is supported by more than 70 peer-reviewed published studies covering all ages from preterm infants to geriatrics and all care areas from hospitals to homes. For additional information, visit www.exergen.com.
_______________________
1 Hayes K, Shepard A, Cesarec A, et al. Cost minimisation analysis of thermometry in two different hospital systems. Postgrad Med J Published Online First: 18 January 2017, doi:10.1136/postgradmedj-2016-134630
2 Kumana C. Minimising the costs of temperature monitoring in hospitals. Postgrad Med J Published Online First: 1 February 2017 doi:10.1136/postgradmedj-2017-134795
Contact: Victoria Day Rosica Public Relations [email protected] P: 201.843.5600 F: 201.843.5680 21-00 Route 208 South Fair Lawn, NJ 07410


Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown
John Ternus Signals Apple’s Future with Product-First AI Strategy
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 



